HYBRIDOMA CORE

杂交瘤核心

基本信息

批准号：
8765391
负责人：
STANTON L. GERSON
金额：
$ 3.3万
依托单位：
CASE WESTERN RESERVE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8765391
关键词：
Affinity Affinity Chromatography Animals Antibodies Antibody Affinity Antigens Area Cancer Center Support Grant Cell Death Cell Differentiation process Cell Line Cells Clinical Comprehensive Cancer Center Consultations Generations Hybridomas Immunoglobulin G Immunoglobulin M In Vitro Instruction Knockout Mice Laboratories Malignant Neoplasms Medical Research Methodology Methods Modeling Modification Monoclonal Antibodies Mus Names Ohio Oryctolagus cuniculus Peer Review Population Preventive Intervention Production Proteins Publications Regulation Resources Scientist Serum-Free Culture Media Services Signal Transduction Speed Spleen Techniques Testing Tissues Training Training and Education Translations Work anticancer research bench to bedside cancer cell cancer therapy cell growth cost effective innovation member monoclonal antibody production novel polyclonal antibody programs repository research study

项目摘要

PROJECT SUMMARY (See instructions): The Case CCC Hybridoma Core provides a cost-effective resource for generating, producing, and purifying monoclonal or polyclonal antibodies, as well as a repository of optimal technical capabilities and innovation regarding all aspects of antibody use. Highly specific monoclonal antibodies are an essential resource in Identifying the levels of expression, specific modifications, and tissue localization of proteins involved in all the functions that control cell growth, cell differentiation, and cell death. The Hybridoma Core continues to work on new methodology related to monoclonal antibodies. The most promising of these is an in vitro method, unique in that it takes advantage of a mouse knockout model that is expected to yield antibodies with IgG isotypes. In test experiments, spleen cells from these mice have remained highly viable in culture during antigen exposure, and have then been used successfully to perform high efficiency fusions resulting in hybridomas. Most importantly, they have confirmed that all of the hybridomas secrete antibodies with an IgG isotype, and in fact can detect no IgM production. The final steps before the Core offers this novel service will be to generate clones and determine the affinity of the resulting monoclonal. This technique should be particularly useful in developing antibodies against mouse antigens, or any antibodies that could be potentially deleterious to a mouse. It also has the potential to virtually eliminate the need for animal use in generating mouse monoclonal. Highly specific monoclonal antibodies are essential to identifying the functions and interactions of proteins involved in cell growth, cell differentiation and cell death, and therefore constitute a major contribution to cancer research. Since 2007, the Core has generated a total of 50 new monoclonal antibodies, and produced monoclonal in serum-free medium for 139 projects; approximately half of which are cancer-related. It is difficult to quantify the number of peer-reviewed publications the Core has facilitated; however, the number is certain to be an underestimate of its impact, because the usefulness of novel antibodies continues to accumulate over many years and in many different scientific areas. The Core primarily works with members from the Cell Death Regulation and Cancer Cell Signaling Programs producing antibodies to such proteins as: phospho-EI, Np65, K218me, and K221me2.

项目摘要（请参阅说明）：CCC CCC杂交瘤核心提供了一种具有成本效益的资源，用于生成，生产和净化单克隆或多克隆抗体，以及有关抗体使用所有方面的最佳技术能力和创新的存储库。高度特异性的单克隆抗体是识别参与所有功能的蛋白质的表达水平，特定修饰和组织定位水平的必不可少的资源，这些功能控制了细胞生长，细胞分化和细胞死亡。杂交瘤核心继续致力于与单克隆抗体有关的新方法。这些最有希望的是一种体外方法，它是独一无二的，因为它利用了小鼠敲除模型，该模型有望产生具有IgG同型的抗体。在测试实验中，这些小鼠的脾细胞在抗原暴露期间在培养中保持很高，然后成功地用于执行高效融合，导致杂交瘤。最重要的是，他们已经确认所有杂交瘤都具有IgG同种型的分泌抗体，实际上可以检测到IgM的产生。核心提供此新颖服务的最后一步将是生成克隆并确定所得单克隆的亲和力。该技术应在开发针对小鼠抗原的抗体或可能对小鼠有害的任何抗体中特别有用。它还有可能实际上消除了在产生小鼠单克隆中使用动物的需求。高度特异性的单克隆抗体对于确定与细胞生长，细胞分化和细胞死亡有关的蛋白质的功能和相互作用至关重要，因此构成了对癌症研究的主要贡献。自2007年以来，该核心总共产生了50种新的单克隆抗体，并在无血清培养基中生产了139个项目的单克隆抗体。大约一半与癌症有关。很难量化核心促进的同行评审出版物的数量。但是，这个数字肯定会低估其影响，因为新型抗体的有用性在多年内和许多不同的科学领域持续积累。该核心主要与细胞死亡调节和癌细胞信号传导程序的成员一起起作用，该蛋白质产生抗体：磷酸化，NP65，K218ME和K221ME2。